Ulcerative Colitis Clinical Trial
Official title:
Ultrasound Guided Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection- a Double Blind Randomised Controlled Trial
Laparoscopic (key-hole) large bowel resection is a minimally invasive procedure when compared
to open large bowel resection, but is still associated with a significant amount of pain and
discomfort. Analgesia is commonly provided by a multi-modal technique involving varying
combinations of paracetamol, Non steroidal anti-inflammatory drugs (NSAIDs), regional
analgesia and oral or parenteral opioids. While epidural analgesia is considered the gold
standard for open colo-rectal procedures it can be associated with significant complications
and may delay hospital discharge in laparoscopic procedures. Opioids are associated with an
increased incidence of nausea, vomiting and sedation and reduced bowel motility which can
also prolong recovery.
Transversus Abdominis Plane (TAP) block is a technique which numbs the nerves carrying pain
sensation from the abdominal wall and provides effective and safe analgesia with minimal
systemic side effects. Their perceived benefits are thought to relate to reduced opioid
consumption and therefore reduced opioid side effects. The investigators believe ultrasound
guided TAP blocks will reduce pain and morphine consumption with a resultant improved patient
satisfaction, earlier return of bowel function and earlier hospital discharge.
The key research question the investigators are trying to answer is whether TAP block provide
better pain relief than local anaesthetic infiltration of the laparoscopic port sites. Both
techniques are currently being used in our hospital and a retrospective audit demonstrated
better analgesia and lower consumption of morphine in the TAP block group.The differences
were not statistically significant as the number patients in the audit were not large
enough.The investigators are hoping that this study will demonstrate that the difference is
real by recruiting the necessary number of patients into each group (36 per group)
Summary of Study Design The study will be a double blind randomised controlled trial with
patients undergoing laparoscopic right hemicolectomy or laparoscopic high anterior resection
randomly allocated into two groups, with the study group receiving bilateral TAP blocks
followed by a morphine PCA and the control group receiving local anaesthetic infiltration of
the laparoscopic port sites and specimen extraction site and a morphine PCA.
A double blind design was chosen to eliminate patient and observer bias in reporting of pain
scores.
The presence of the control arm will ensure that any difference observed will be due to the
effect of sensory nerve block due to the TAP block than due to the systemic effect of the
injected local anaesthetic.
The null hypothesis will be that there is no difference between the groups in the amount of
morphine consumed by the patients during 48 hours after the operation. We chose this
measurement as an objective but indirect measurement of efficacy of TAP block and pain relief
thus received. Measurement of pain with various scoring methods are reliable only when
concurrent reduction in consumption of pain killers are demonstrated.
Recruitment and randomisation:
All patients meeting the inclusion criteria will receive a patient information leaflet and an
invitation letter to participate in the study during the pre-assessment visit. We aim to
recruit 72 patients (36 patients per group).
Informed consent will be taken by one of the investigators on the morning of the surgery, if
the exclusion criteria are not applicable. Patients will be allotted consecutive participant
numbers starting from one. Patients will be randomly allocated into either the study group
and a control group. Randomisation will occur by using computer generated random numbers.
Group allocation will be kept in a consecutively numbered, opaque, sealed envelope in the
controlled drugs cupboard in theatre-6 anaesthetic room of Churchill hospital.Once patient
has consented, the anaesthetist will open the corresponding numbered envelope and perform
bilateral TAP blocks after induction of general anaesthesia, if the patient is in the study
group the surgeons will infiltrate the port sites with local anaesthetic at the end of the
procedure if the patient is in the control group.
Blinding:
The study group will receive bilateral TAP blocks with 20mls 0.25% bupivacaine on each side
and the skin punctures on either sides will be covered with a small plaster. Patients in the
control group will receive subcutaneous infiltration of the laparoscopic port sites and
specimen extraction site with equivalent amount bupivacaine at the end of the procedure and
small plasters will be stuck on either flanks approximately where the skin punctures for TAP
block will be made.
The assessor of pain scores and morphine doses (Recovery nurse & Colo-rectal house officer)
and the patient will be blinded to group allocation.
Patient: Plasters will be stuck on flanks of all the patients both study and control group so
that patient will not know if they have received TAP block.
Recovery nurse: During handover to recovery the anaesthetist and scrub nurse will not mention
about group allocation.
Colo-rectal house officer: The house officers( Junior Doctors) who will be following up in
the ward will not present in the operating theatre, so they will be blinded
The study duration will be from induction of anaesthesia until the patients are medically fit
for discharge from hospital. No extra visits other than routinely required for the surgical
procedure is expected.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |